AU2021244228A1 - Technologies for preventing or treating infections - Google Patents

Technologies for preventing or treating infections Download PDF

Info

Publication number
AU2021244228A1
AU2021244228A1 AU2021244228A AU2021244228A AU2021244228A1 AU 2021244228 A1 AU2021244228 A1 AU 2021244228A1 AU 2021244228 A AU2021244228 A AU 2021244228A AU 2021244228 A AU2021244228 A AU 2021244228A AU 2021244228 A1 AU2021244228 A1 AU 2021244228A1
Authority
AU
Australia
Prior art keywords
xaa
agent
amino acid
independently
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021244228A
Other languages
English (en)
Inventor
Alexander Sergei BAYDEN
Tetyana Berbasova
Lawrence Emerson Fisher
Wieslaw Kazmierski
Luca Rastelli
Tomi K. Sawyer
David Adam SPIEGEL
Wayne Charles Widdison
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Therapeutics Ltd
Original Assignee
Biohaven Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd filed Critical Biohaven Therapeutics Ltd
Publication of AU2021244228A1 publication Critical patent/AU2021244228A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2021244228A 2020-03-25 2021-03-25 Technologies for preventing or treating infections Abandoned AU2021244228A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062994779P 2020-03-25 2020-03-25
US62/994,779 2020-03-25
US202063001455P 2020-03-29 2020-03-29
US63/001,455 2020-03-29
US202063055860P 2020-07-23 2020-07-23
US63/055,860 2020-07-23
PCT/US2021/024186 WO2021195401A1 (en) 2020-03-25 2021-03-25 Technologies for preventing or treating infections

Publications (1)

Publication Number Publication Date
AU2021244228A1 true AU2021244228A1 (en) 2022-11-17

Family

ID=77890439

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021244228A Abandoned AU2021244228A1 (en) 2020-03-25 2021-03-25 Technologies for preventing or treating infections

Country Status (12)

Country Link
US (1) US20230330240A1 (https=)
EP (1) EP4125893A4 (https=)
JP (1) JP2023520188A (https=)
KR (1) KR20220158762A (https=)
CN (1) CN115697415A (https=)
AU (1) AU2021244228A1 (https=)
BR (1) BR112022018945A2 (https=)
CA (1) CA3176256A1 (https=)
IL (1) IL296725A (https=)
MX (1) MX2022011692A (https=)
PH (1) PH12022552499A1 (https=)
WO (1) WO2021195401A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159372A1 (en) 2021-01-22 2022-07-28 Decoy Therapeutics, Inc. Methods and compositions for treating infections
WO2023150375A2 (en) * 2022-02-07 2023-08-10 Decoy Therapeutics Inc. Methods and compositions for treating covid infections
CN116440285A (zh) * 2023-04-19 2023-07-18 山西锦波生物医药股份有限公司 冠状病毒多肽类融合抑制剂的长效化的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3069986A1 (en) * 2017-07-26 2019-01-31 Kleo Pharmaceuticals, Inc. Universal abt compounds and uses thereof

Also Published As

Publication number Publication date
US20230330240A1 (en) 2023-10-19
MX2022011692A (es) 2023-02-09
BR112022018945A2 (pt) 2022-12-13
JP2023520188A (ja) 2023-05-16
CA3176256A1 (en) 2021-09-30
EP4125893A4 (en) 2024-10-16
EP4125893A1 (en) 2023-02-08
KR20220158762A (ko) 2022-12-01
PH12022552499A1 (en) 2024-03-25
IL296725A (en) 2022-11-01
WO2021195401A1 (en) 2021-09-30
CN115697415A (zh) 2023-02-03

Similar Documents

Publication Publication Date Title
JP2023501720A (ja) 指向性コンジュゲーション技術
AU2021244228A1 (en) Technologies for preventing or treating infections
CN116323638A (zh) 订书钉化肽及其方法
JP7793506B2 (ja) Cd38に結合する薬剤およびその使用
JP2024164029A (ja) Armおよびナチュラルキラー細胞の併用療法
CA3219550A1 (en) Antibody drug conjugates using mates technology for delivering cytotoxic agents
EP4288110A2 (en) Technologies for preventing or treating infections
JP2025541246A (ja) ステープルペプチドおよびその方法
JP2025541247A (ja) ステープルペプチドおよびその方法
HK40128981A (zh) 订书钉化肽及其方法
HK40129655A (zh) 订书钉化肽及其方法
EA050690B1 (ru) Комбинированная терапия arm и естественными клетками-киллерами
WO2024228957A1 (en) Antibody recruiting molecules for the treatment of coronavirus disease-19

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period